Caroline M Loewy
CIK 1367451 · Chief Financial Officer · last filed 2024-06-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PARDD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
SEATTLE, WA 98119-4114
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Director | — | $0.00 | — | $0 | 3 | 2024-06-13 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | — | $32.48 | — | $0 | 11 | 2024-03-22 |
| CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Director | 5,828 | $0.05 | $292 | $0 | 1 | 2024-02-16 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Director | — | $0.07 | — | $0 | 5 | 2022-05-20 |
| Aptose Biosciences Inc. (APTO) Delisted | Director | — | $1.71 | — | $0 | 6 | 2022-01-20 |
| CERO THERAPEUTICS HOLDINGS, INC. (PBAXU) Delisted | Director | — | $10.37 | — | $0 | 1 | 2021-10-12 |
| ZOGENIX, INC. (ZGNX) Delisted | Director | — | $26.68 | — | $0 | 2 | 2021-05-28 |
| LWACU | Director | — | $10.36 | — | $0 | 1 | 2021-01-14 |
| CORT | Chief Financial Officer | — | $85.57 | — | $0 | 1 | 2008-12-02 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | CFO | 29,900 | — | — | $109.8K | 5 | 2008-03-06 |
Recent Filings · Page 3 of 4
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-19 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-13 | Aptose Biosciences Inc. (APTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-13 | Aptose Biosciences Inc. (APTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-03 | Aptose Biosciences Inc. (APTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-13 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-01 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-31 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-03 | Aptose Biosciences Inc. (APTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.